Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Mallinckrodt plc
  6. Company
    MNKKQ   IE00BBGT3753

MALLINCKRODT PLC

(MNKKQ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Business Summary
Logo Mallinckrodt plc
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Number of employees : 3 100 people.
Sales per Business
2020
Specialty Brands2 059.6093.1%
Specialty Generics689.8031.2%
USD in Million
Sales per region
2020
United States2 465.50111.4%
Europe, Middle East and Africa227.5010.3%
Other56.402.5%
USD in Million
Managers
Name Title Age Since
Mark Trudeau President, Chief Executive Officer & Director 58 2013
Bryan Marlen Reasons Chief Financial Officer & Executive Vice President 52 2019
Steven Joseph Romano, Dr. Chief Scientific Officer & Executive VP 60 2015
Babatunde Adekunle Otulana, Dr. Chief Medical Officer & Senior Vice President 63 2016
Hugh M. Oneill Chief Operations & Commercial Officer, EVP 56 -
JoAnn A. Reed Independent Director 64 2013
Kneeland C. Youngblood, Dr. Independent Director 64 2013
J. Martin Carroll Independent Director 70 2013
David R. Carlucci Independent Director 65 2013
Angus C. Russell Chairman 64 2018
Members of the board
Name Title Age Since
Angus C. Russell Chairman 64 2018
JoAnn A. Reed Independent Director 64 2013
Mark Trudeau President, Chief Executive Officer & Director 58 2013
Kneeland C. Youngblood, Dr. Independent Director 64 2013
J. Martin Carroll Independent Director 70 2013
David R. Carlucci Independent Director 65 2013
David York Norton Independent Director 67 2017
Anne Michelle Clem Whitaker Independent Director 52 2018
Paul Rutherford Carter Independent Director 59 2018
Carlos V. Paya, Dr. Independent Director 61 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 94,280,086 78,133,411 82.9% 9,564,208 10.1% 82.9%
Shareholders
NameEquities%
JANA Partners LLC 5,725,711 6.76%
The Vanguard Group, Inc. 5,483,980 6.47%
Scopia Capital Management LP 4,724,581 5.58%
Dimensional Fund Advisors LP 4,166,260 4.92%
Viking Global Investors LP 3,911,692 4.62%
Morgan Stanley & Co. LLC 2,807,398 3.31%
Institutional Capital LLC 2,776,033 3.28%
Armistice Capital LLC 2,678,000 3.16%
SSgA Funds Management, Inc. 2,543,950 3.00%
BlackRock Fund Advisors 2,420,420 2.86%
Holdings
NameEquities%Valuation
SILENCE THERAPEUTICS PLC (SLN) 5,062,167 5.64% 35,561,217 USD
Brand Portfolio
In partnership withAllbrands.markets
More brands of Mallinckrodt plc
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
MALLINCKRODT PLC-27.25%15
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231
MERCK & CO., INC.0.55%208 206
ABBVIE INC.2.18%193 488
ASTRAZENECA PLC22.92%192 243
NOVARTIS AG-6.91%189 275
BRISTOL-MYERS SQUIBB COMPANY-6.11%129 416
SANOFI8.83%124 649
AMGEN INC.-9.24%118 499
GLAXOSMITHKLINE PLC6.87%98 943
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-21.86%61 190
BAYER AG1.32%55 574
JIANGSU HENGRUI MEDICINE CO., LTD.-47.18%49 318
DAIICHI SANKYO COMPANY, LIMITED-18.42%47 906
TAKEDA PHARMACEUTICAL COMPANY LIMITED-15.02%43 832
ASTELLAS PHARMA INC.23.43%31 917